At Elise Biopharma, we recognize that single‑domain antibodies (VHH nanobodies) are reshaping the future of veterinary therapeutics. Their small size, remarkable stability, and ease of engineering make VHHs ideal for applications ranging from oncology to ophthalmology and toxin neutralization in dogs, cats, and horses. Backed by a Quality by Design (QbD) approach and our end‑to‑end CDMO infrastructure, we deliver turnkey VHH discovery, development, and GMP manufacturing—so you can bring next‑generation biologics to market faster, safer, and more cost‑effectively.
1. What Are VHH Nanobodies?
VHH nanobodies are the variable domains of heavy‑chain‑only antibodies naturally found in camelids (e.g., llamas, alpacas). Unlike conventional antibodies, VHHs consist of a single ~15 kDa domain, conferring:
- Ultra‑Small Size
Penetrates dense tissues and crosses biological barriers more effectively than full‑length IgGs. - Exceptional Stability
Tolerates extremes of pH and temperature, enabling oral or topical formulations and simplifying cold‑chain requirements. - High Affinity & Specificity
Engineered through display technologies to bind targets with sub‑nanomolar affinities. - Low Immunogenicity
Humanization strategies minimize adverse immune responses, even when used across species.
These properties open novel routes for treating cancer, inflammatory disorders, infectious diseases, and toxin exposures in companion animals.
2. Quality by Design & Seamless Workflow
From antigen to commercial supply, our VHH services are built upon QbD principles:
- Target Product Profile (TPP) Definition
We partner with you to define critical quality attributes (CQAs) such as binding affinity, thermal stability, and formulation characteristics tailored for veterinary use. - Design of Experiments (DoE)
Systematic exploration of:- CDR loop libraries
- Expression host and induction conditions
- Purification parameters
- Critical Process Parameters (CPPs) & Controls
Real‑time monitoring of fermentation temperature, pH, and feed rates; inline analytics ensure consistent yield and quality. - Risk Assessment & Mitigation
Comprehensive FMEA identifies potential failure modes (e.g., aggregation, endotoxin carry‑over) and integrates mitigation steps—such as multi‑step purification and stringent in‑process testing. - Continuous Improvement
Post‑batch reviews inform iterative enhancements to maximize process robustness and regulatory confidence.
By embedding QbD from discovery through GMP production, we de‑risk scale‑up challenges and streamline regulatory approval.
3. Discovery & Engineering Services
Elise Biopharma offers a full suite of discovery tools to generate lead VHH candidates:
- Antigen Design & Preparation
Recombinant protein or peptide immunogens optimized for immune response in camelids and for downstream expression. - Immunization & Library Generation
Llamas or alpacas are immunized following animal‑welfare protocols; peripheral blood lymphocytes are harvested to construct phage or yeast display libraries. - High‑Throughput Screening
- Phage/yeast panning rounds to enrich binders
- ELISA and BLI/SPR assays to quantify binding kinetics (KD, kon/koff)
- Cell‑based functional assays for neutralization or receptor blockade
- Affinity Maturation & Humanization
CDR mutagenesis and homologous framework grafting enhance potency while minimizing immunogenic motifs. - In Silico Developability Assessment
Computational analysis flags liabilities—such as aggregation hotspots or deamidation sites—prior to experimental validation.
These integrated discovery services yield fully characterized VHH leads ready for scale‑up.
4. Drug Substance Production
Once lead candidates are selected, our manufacturing team executes a QbD‑driven process for clinical‑ and commercial‑grade drug substance:
- Microbial Expression
- Host platforms: E. coli, Pichia pastoris, or other custom strains
- Fed‑batch fermentation in bioreactors (50–2 000 L)
- Real‑time monitoring of cell density, dissolved oxygen, and nutrient feeds
- Downstream Purification
- Capture chromatography (Protein A/G or affinity tags)
- Intermediate polishing (ion‑exchange, hydrophobic‑interaction)
- Size‑exclusion chromatography for final purity and aggregate removal
- Viral & Endotoxin Clearance
- Low‑pH viral inactivation steps
- Depth filtration and high‑capacity membranes to reduce bioburden
- Endotoxin testing at <0.1 EU/mg for injectable formulations
- Concentration & Formulation Buffer Exchange
- Tangential flow filtration (TFF) to achieve target concentration
- Buffer optimization for stability and delivery (pH, excipient screening)
Our robust drug‑substance pipeline delivers >95 % purity and consistent yield across scales.
5. Formulation & Finished‑Dose Expertise
Veterinary therapeutics demand flexible dosage forms that suit administration routes, animal behavior, and market economics. We excel in:
A. Sterile Injectables
- Formats: vials, pre‑filled syringes, lyophilized powders
- Applications: oncology, anti‑toxin therapies, systemic inflammatory diseases
- Key Capabilities: aseptic filling, lyophilization cycle development, container‑closure integrity testing
B. Topicals & Spot‑Ons
- Formats: creams, gels, sprays, spot‑on pipettes
- Applications: dermatology, ophthalmology, localized infections
- Features: optimized viscosity, skin penetration enhancers, preservative strategies
C. Oral Palatable Soft Chews
- Formats: chewables, tablets, palate‑tested formulations
- Applications: anti‑inflammatory, metabolic disorders, prophylactic vaccines
- Palatability Enhancers: taste‑masking agents, flavor blends, texturizers
D. Advanced Delivery Systems
- Conjugates: Fc‑fusion or albumin‑binding for half‑life extension
- Multivalent Constructs: bispecific or fusion proteins for combinatorial targeting
Each dosage form undergoes VICH stability testing, forced‑degradation studies, and real‑time shelf‑life assessment to ensure field readiness.
6. Analytical & Regulatory Support
Meeting global veterinary regulations requires robust analytical packages and dossier preparation:
- Analytical Method Development
- Binding Kinetics: SPR/BLI for KD, kon, koff
- Purity & Aggregation: SEC‑HPLC, CE‑SDS, dynamic light scattering
- Potency Assays: cell‑based neutralization, receptor‑binding ELISA
- Safety Testing: endotoxin, sterility, host‑cell protein/DNA quantification
- Method Validation
- Full validation protocols (accuracy, precision, linearity, specificity) per VICH Q2(R1) guidelines.
- Transferable SOPs and validation reports for client or CDFA review.
- CMC Dossier Preparation
- eCTD‑ready modules covering drug‑substance and drug‑product attributes
- Risk‑based comparability with reference biologics or human precedents
- Change control and lifecycle management plans for post‑approval updates
- Regulatory Strategy & Consulting
- FDA CVM pre‑IND and NADA support
- EMA VICH harmonization guidance
- Labeling, environmental risk assessment, and field‑trial authorization
Our regulatory experts minimize review cycles and accelerate path to market.
7. Applications & Case Studies
Canine Anti‑IL‑6 Soft Chew for Osteoarthritis
- Challenge: Chronic joint inflammation in senior dogs demands daily dosing with high compliance.
- Solution: VHH targeting canine IL‑6 receptor, formulated into a palatable chew with taste‑masking and sustained release.
- Outcome: 75 % reduction in lameness score in pilot field trials; shelf‑stable at room temperature for 12 months.
Feline Anti‑TNFα Topical Gel for Dermatitis
- Challenge: Topical therapy needed for localized skin inflammation without systemic side effects.
- Solution: Nanobody‑gel combination enabling high local concentration and minimal systemic absorption.
- Outcome: 60 % improvement in lesion severity after 4 weeks; no adverse reactions reported.
Equine Anti‑Venom Injectable for Snake‑Bite Neutralization
- Challenge: Rapid neutralization of diverse snake toxins in horses used for agricultural work.
- Solution: Broad‑spectrum VHH cocktail produced at 500 L scale, delivered in pre‑filled syringes for immediate use.
- Outcome: 90 % survival rate in challenge studies; technology transferred to fill/finish partner seamlessly.
These examples illustrate the breadth and depth of our VHH CDMO expertise.
8. Scale‑Up & Commercial Launch
From bench to barn, Elise Biopharma’s infrastructure supports every scaling stage:
| Scale Level | Volume Range | Purpose |
|---|---|---|
| Laboratory Scale | 2–10 L | Feasibility, DoE, early process definition |
| Pilot Scale | 50–200 L | Tech‑transfer batches, process optimization |
| Commercial Scale | 500–2 000 L | Full‑scale production, bulk drug substance |
| Fill/Finish Partners | — | Aseptic filling, packaging, labeling |
- On‑Time, In‑Full (OTIF) Pledge
Coordinated raw‑material sourcing, capacity reservation, and batch scheduling assure reliable supply—even during seasonal or outbreak‑driven demand spikes. - Supply Chain Resilience
Dual‑sourcing of critical resins and excipients, plus strategic inventory buffers, minimize disruption risk. - Flexible Packaging Solutions
Bulk or finished‑dose options with cold‑chain, controlled‑room‑temperature, or lyophilized kits.
Whether you need 100 mg for pilot studies or kilograms for commercial launch, our teams ensure seamless execution and traceability.
9. Why Partner with Elise Biopharma?
- Dedicated Companion‑Animal Focus
Expertise in dosing, administration, and market needs specific to dogs, cats, and horses. - QbD‑Backed Science & Engineering
Rigorous process definition and risk mitigation from antigen to market. - Multi‑Modality Dosage Capabilities
Injectables, topicals, orals, and advanced conjugates—tailored to your therapeutic goals. - Global Regulatory Mastery
In‑depth knowledge of FDA CVM, EMA VICH, and emerging markets. - Agile Project Management
Responsive cross‑functional teams keep you informed, on time, and on budget. - Proven Track Record
Successful technical transfers, rapid scale‑up, and high client satisfaction across multiple animal‑health programs.
10. Next Steps
Are you ready to develop breakthrough VHH nanobody therapeutics for companion animals? Email us at info@elisebiopharma.com or use form below.